Your session is about to expire
← Back to Search
Calcium Channel Blocker
Medical Therapy for Myocardial Bridging
Phase 2
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial is important because it will help doctors better diagnose and treat a heart condition that affects a lot of people.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo
Secondary outcome measures
Changes in exercise capacity.
Other outcome measures
Drug adherence.
Side effects.
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: Beta Blocker (nebivolol)Active Control1 Intervention
Group II: Calcium Channel Blocker (diltiazem)Active Control1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,408 Previous Clinical Trials
17,342,847 Total Patients Enrolled
1 Trials studying Myocardial Bridging
150 Patients Enrolled for Myocardial Bridging
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your heart has a lower than normal pumping ability.You had a very bad reaction to beta blockers or calcium channel blockers in the past.Your blood pressure is lower than 100 over 0 or your heart beats slower than 50 times per minute when you are resting.You are 18 years old or older.You have stable chest pain that fits specific criteria.You do not want to take beta blockers or calcium channel blockers.You have recently experienced a serious heart condition like unstable angina, heart attack, or cardiogenic shock.You have had a heart transplant in the past.You have another condition that could explain your chest pain, like lung pressure, heart muscle thickening, or narrowed aortic valve.You don't have any symptoms.You do not have blockages in your heart arteries, as shown by specific tests.You are taking a medication that can have a harmful interaction with beta blockers or calcium channel blockers.You have had an exercise stress test in the past six months.You have had a test that shows you have a condition called myocardial bridge.
Research Study Groups:
This trial has the following groups:- Group 1: Beta Blocker (nebivolol)
- Group 2: Calcium Channel Blocker (diltiazem)
- Group 3: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger